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Abstract 
Growth factors and other therapeutic protein that could potentially enhance tissue regeneration have 
been identified, but their therapeutic value in clinical medicine has been almost non-existent for 
reasons such as difficulty to maintain bioactivity of locally applied proteins in the protease-rich 
environment of regenerating tissues. Although human diseases are treated with systemically 
administered drugs in general, all current efforts aimed at enhancing tissue repair with biological 
drugs have been based on their local application. The systemic administration of growth factors has 
been ruled out due to concerns about their safety. These concerns are warranted, because only a 
small proportion of systemically administered drugs reach their intended target. Selective delivery of 
the drug to the target tissue and use of functional protein domains capable of penetrating cells and 
tissues could alleviate these problems. We propose a novel approach utilizing unique molecular 
“Zip/postal codes” in the angiogenic vasculature forming at the regenerating tissues as a target for 
systemically administered, targeted therapies. The angiogenic vasculature allows target organ-specific 
delivery of systemically administered therapeutic molecules by affinity-based physical targeting (using 
peptides or antibodies as an “address tag”) to injured tissues undergoing repair. Molecules with 
therapeutic potential can also be packaged into lipid or polymer-based nanocarriers (such as micelles, 
liposomes, and nanoerythrosomes) which then can be targeted to the desired location by inserting 
multiple copies of the targeting peptide on the surface of the nanoparticle. The desired outcome of 
the targeted therapies is increased local accumulation and lower systemic concentration of the 
therapeutic payload. We believe that the physical targeting of systemically administered therapeutic 
recombinant proteins could be rapidly adapted in the field of regenerative medicine. 
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1. Local versus systemic drug delivery in regenerative medicine
After an injury adult tissue react differently. Only some tissues, such as the bone, repair injuries with 
tissue that is identical to the original tissue. Most tissues, however, undergo a repair process where 
most of the injured tissue is replaced by non-functioning, fibrotic scar tissue, whereas the original 
tissue is only partly restored 
1, 2
. 
Plenty of growth factors and other proteins have been identified that could potentially be used as 
drugs to enhance tissue regeneration, but their therapeutic application in regenerative medicine has 
been rather limited 
1, 3, 4
. Only two of them have been approved by FDA to be used in humans; bone 
morphogenetic protein-2 (BMP-2) for treating fractures and platelet derived growth factor (PDGF) for 
treating chronic skin wounds that do not close 
4, 5
. However, neither of these recombinant growth 
factors is in wide use due to rather limited clinical therapeutic value. Furthermore, PDGF received a 
boxed warning from the U.S. Food and Drug Administration and has been withdrawn in Europe due to 
safety issues 
5
. There are several, biological reasons for their failure in randomized clinical trials 
(RCTs): It is difficult to maintain bioactivity of locally administered therapeutic proteins because of a 
lack of retention of the agent within the regenerating tissue, poor tissue penetration, and instability 
of protein therapeutics in the protease-rich environment of the injured tissue, and side effects 
4, 6
. For 
example, when PDGF was used as a topical administration in skin wounds, supra-physiological doses 
were needed and treatment with the growth factor correlated with a five-times increased risk of 
cancer 
5
. The problems encountered with PDGF illustrate well the importance of controlling not just 
the instability of the growth factors, but also their retention at the wound site and overcoming these 
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challenges are probably the key for successful growth factor-based therapies 
5
. Besides, most injuries 
are inaccessible for topically applied therapeutic molecules, especially if the injury hits multiple sites 
(tissues), which further limit the usefulness of local treatment. 
Remarkably, all current efforts, even the most sophisticated ones, aiming to enhance tissue repair 
with biologic drugs have been based on local application of therapeutic molecules at the injured site 
4, 
6, 7
. Although human diseases are treated with systemically administered drugs/recombinant proteins 
in general, systemic application of growth factors has been ruled out due to concerns about efficiency 
and potential safety. These concerns are warranted because the major problems in systemic drug 
therapy are that only a small proportion of administered drug reaches its intended target site(s) and 
as explained above for PDGF side effects such as increased cancer risk 
5
. Moreover, large molecules 
such as antibodies have a poor tissue penetration and therefore do not reach the intended actual 
target cells 
8-11
. Selective drug delivery to the target tissue and use of functional proteins, such as cell 
penetrating peptides proficient of penetrating cells and tissues, could alleviate some of the above 
mentioned problems 
11-14
. 
2. Vascular Heterogeneity – Organ-specific postal code-system in vasculature
Our growing knowledge of the molecular structure of blood vessels has revealed a practical 
application for organ/tissue-specific therapeutic treatment of various human diseases with 
systemically administered drugs 
8, 12, 13
. Recent studies have shown that each organ has unique 
molecular structures in its blood vessels, so-called “vascular ZIP codes”, essentially providing a built-in 
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postal code system in our body (Figure 1) 
12, 13, 15-17
. Each organ confers endothelial cells (ECs) in it 
with their “organotypic”, i.e. unique tissue-specific features 
18, 19
. A unique combination of clusters of 
transcription factors, angiocrine growth factors, adhesion molecules and chemokines is expressed by 
the ECs of each organ, and so the blood vessels in each organ can be distinctly defined 
19
. Moreover, 
during various diseases, disease-specific signatures are expressed on the vasculature of the diseased 
tissue 
17
. This is particular apparent for diseases such as cancer, or tissue injuries, which both induce 
the growth of new blood vessels into the tissue by angiogenesis 
17
. These angiogenic blood vessels are 
structurally distinct from the pre-existing blood vessels in rest of the body 
17
 and thus, provide an 
appealing target for target organ-specific delivery of systemically administered drugs. 
Hence, the disease and organ-specific molecular “Zip codes” in blood vessels can be exploited for 
target organ-specific delivery (to the diseased tissue) of systemically administered therapeutic 
molecules by affinity ligands 
12, 15-17
. This so-called affinity-based physical targeting (synaphic, 
pathotrophic, or active targeting) makes use of these vascular ZIP codes, i.e. molecular markers that 
are specifically expressed at the target, but not elsewhere in the body on healthy counterparts, 
12, 17
. 
The desired outcome of the synaphic targeting is increased local accumulation and lower systemic 
concentration of the therapeutic payload 
12
. 
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Figure 1. Target-specific drug therapies in tissue regeneration. Molecular “Zip/postal codes” in 
the angiogenic vasculature of the regenerating tissues allow target organ-specific delivery of the 
systemically administered therapeutic recombinant proteins by affinity-based physical targeting 
(using peptides or antibodies as an “address tag”) to injured tissues undergoing repair. The 
desired outcome of the targeted therapies is similar to topical application: increased local 
accumulation of the recombinant protein in the target tissue and lower systemic concentration 
of the therapeutic payload. 
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3. Angiogenesis – a potential for vascular targeting in regenerative medicine
Angiogenesis, the formation of new blood vessels, is an essential step for tissue regeneration because 
it allows a variety of mediators, nutrients, and oxygen to reach the healing tissue 
1-3, 20, 21
. During 
regeneration of injured tissue, angiogenic capillary sprouts invade the fibrin/fibronectin-rich clot and 
within a few days form up into a thick microvascular network throughout the granulation tissue 
1-3, 20,
22
. These newly formed blood vessels that abundantly fill up and from the granulation tissue at the 
site of the injury, differ in their molecular “Zip/postal codes”” from pre-existing vasculature. 
Therefore they provide a fascinating possibility for vascular targeting of systemically administered 
drugs to improve tissue regeneration 
22, 23
. 
4. In vivo phage display
Tissue specific vascular “ZIP codes” can be easily probed by in vivo phage display, a method first 
reported in 1996 
24
. In vivo phage display allows unbiased investigation of vascular diversity by 
random peptide or cDNA libraries expressed as a part of the coat protein on the cell surface of 
bacteriophages (Figure 2) 
13, 25
. Due to the random protein fragments being the only difference 
between different phage particles in the library, phage display is a powerful method for screening an 
unlimited number of potential functional protein domains, because it provides a physical linkage 
between peptides (i.e. the phenotype), which are displayed on the surface of a bacteriophage 
particle, and the encoding DNA (genotype) 
13, 25
. 
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Figure 2. Schematic presentation of the principle of in vivo phage display. (a) A cyclic CX7C-
peptide library has been cloned to the C-terminus of the phage coat protein and expressed in 
415 copies in T7 Select 415-1b phage. (b) A phage library is injected into circulation. The homing 
peptides on the phage surface bind to endothelium in the tissues, resulting in an enrichment of 
phages bound to the endothelium of the target tissue. Target tissue is homogenized, cell 
suspensions prepared, and the bound phage rescued and amplified by adding E. coli. The 
amplified phage pool recovered from the target tissue is then re-injected into mice at a similar 
disease stage, and the screening cycle is repeated several times to ensure that phage clones 
that specifically bind (i.e. home) towards target will be recovered. A set of phage clones is 
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randomly collected from a homing phage population that shows enriched homing towards 
target tissue. The peptide-encoding DNA inserts are amplified by PCR, and the PCR products 
sequenced. 
Bacteriophages can be genetically modified to incorporate random protein sequences fused to the 
coat proteins at a diversity of billions of variants per library, close to the total number of possible 
permutations (20
X
, where X denotes number of amino acids) of a random amino acid sequence 
13
. 
Generating a random phage library results in a pool of billions of bacteriophages all identical to each 
other except for the protein motif expressed at the end of its coat protein. For the in vivo selection, a 
library of phage displaying random peptides is injected systemically into the animals, followed by 
removal of target organ/tissue and amplification of the bound phage pool from the target organ, 
which is then subjected to another round of selection in new animals 
13
. In vivo peptide phage 
screening combines subtractive elements (removal of phage displaying pan-specific peptides by all 
other organs of the body except the given target organ) with positive selection at the target tissue 
13
. 
In vivo phage display offers a unique prospect to screen for an almost unlimited (potentially billions) 
number of potential protein-based drug candidates simultaneously in an in vivo setting 
13, 25
. 
Combination of in vivo phage display and bacterial 2-hybridization, in turn, allows simultaneous 
identification of ligand-receptor (ligand – peptide; receptor – receptors on the endothelial cells) pairs 
for the target organ-specific targeting 
26
. 
In the field of regenerative medicine  in vivo phage display has been applied for several purposes: to 
identify peptides capable of binding to the blood clots formed after the injury 
27
, homing to the 
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angiogenic blood vessels forming at the injured tissues 
28
, for the identification and illumination of 
neural structures during surgery 
29, 30
 and to identify peptides capable of homing to brain injury after 
the traumatic breakage of blood-brain barrier 
31
. 
5. Systemically administered vascular homing peptides for regenerative medicine
We concluded that it may be achievable to deliver systemically administered drugs into regenerating 
tissues via a target organ-specific approach independent of the location of the injury in the body 
28
. 
For that purpose, in vivo phage display was used on injured tissues during angiogenesis to identify 
protein motifs capable of homing to the injured sites after systemic administration of phage libraries 
28
. Two peptides that selectively target injured tissues have been identified: CARSKNKDC (CAR) and 
CRKDKC (CRK) 
28
. The CAR sequence is homologous to heparin-binding sites in various proteins and 
shows the highest homology with the main heparin-binding site of known angiogenic growth factor, 
BMP4 
28
. Indeed, the CAR peptide binds to cell surface heparan sulfate proteoglycans (HSPGs) and 
utilizes the HSPGs for efficient cell and tissue penetration 
28
. The CRK peptide which is not capable of 
cell and tissue penetration 
28, 32
 shows structural similarity to segments in thrombospondin type 1 and 
3 repeats identified in numerous proteins and has a potential cryptic cell penetration sequence, 
CendR-sequence in it 
28
. These two vascular homing peptides have different targeting profiles: CAR 
peptide prefers early stages of tissue regeneration, whereas the CRK peptide preferably targets 
injured tissues at later stages of healing 
28
. 
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6. Conjugated delivery – Multi-functional recombinant proteins
By conjugating a conventional therapeutic effector molecule to a targeting element, a tissue-specific 
targeted, multi-functional therapeutic molecule is created. The conjugation of these two functional 
elements can be either carried out by chemical linkage or by expressing them together as a 
recombinant fusion protein. An example of such recombinant fusion protein is interleukin-10 (IL-10) 
fused to the antibody F8 (F8-IL10, i.e. Dekavil) that recognizes a domain of the extracellular matrix 
protein fibronectin, that is expressed exclusively in inflammatory vasculature 
33-36
. This therapeutic 
fusion protein is in ongoing clinical trials to treat arthritis and to suppress rejection towards allografts 
in transplantation surgery 
34, 36
. Additional examples include Angiopep, a peptide used to target 
nanoparticles loaded with therapeutic molecules to brains in e.g. Parkinson’s disease 
14
, the tumor 
homing NRG-peptide fused together with tumor necrosis factor α (TNFα) to induce anti-tumor 
reactions towards tumor cells 
37, 38
, interleukin-11 (IL-11) mimic peptide motif fused together with 
apoptosis inducing peptide sequence to halt tumor growth 
39
 and RGR peptide expressed together 
with LIGHT protein to stabilize leaky, non-functional blood vessels 
40
. 
The half-life of the most common peptides used as targeting elements, is usually short in blood 
circulation and their binding affinity for their respective receptor relatively low 
22
. However, both of 
these shortcomings can be substantially minimized by fusing the peptides to become a part of a larger 
recombinant protein or by coating cells or nanoparticles with multiple copies of the peptide 
12, 22, 41
. 
For example, our preliminary data provide evidence that incorporation of CAR peptide into 
therapeutic proteins enhances their binding efficacy towards HSPGs to a nanomolar-level, and even 
more if the recombinant fusion protein is multimerized (expressed as a dimer) (unpublished). One-to-
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one peptide-payload (i.e. targeting element-therapeutic effector) conjugates can be quite effective 
despite the large size difference, particularly when the peptide is used to augment an inherent affinity 
of the payload to the target. Such examples are TNFα targeted to tumors by fusion to a tumor-homing 
peptide that is now in phase 3 clinical trials 
37, 38
, and CAR-peptide targeted decorin (DCN) 
42
. DCN 
homes to angiogenic vasculature through a core protein-dependent interaction 
43
, but despite its 
inherent homing ability, the CAR peptide was able to enhance the accumulation of the recombinant 
fusion protein into the sites of angiogenesis (wound) approximately 500 % over the accumulation of 
native DCN 
42
. Furthermore, a prime example of using multiple copies of a short targeting peptide 
(“painting”) is the targeting of stem cells to desired loci 
41, 44
. Both CAR and CRK peptides have been 
used successfully, e.g. to target mesenchymal stem cells (MSCs) to infarcted myocardium after 
“painting” the surface of MSCs with multiple copies of the peptide 
41, 44
. 
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Figure 3. Systemically administered, targeted therapies. (a) Conjugated delivery. The drugs are 
physically conjugated to the targeting element in conventional drug targeting. For protein-based 
therapeutics, targeting domain and therapeutic molecule are fused together as a recombinant 
protein with enhanced activity and tissue-specificity. (b) – (c) Bystander effect. Therapeutic 
drug(s) co-injected with tissue-penetrating targeting peptides are transported across the vessel 
wall and through tissue together with the peptides. No actual physical connection is needed 
between them; the cell penetrating homing peptide “sweeps” co-injected drug(s) to its target 
(homing) tissue in a tissue-specific fashion. 
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Even more striking is the finding that the targeting domain is capable of increasing the activity of the 
therapeutic molecule. We have discovered that a vascular homing peptide for a tissue or lesion often 
also binds to the corresponding parenchymal cells. This is the case with CAR, which also recognizes 
the cells in the granulation tissue in wounds. This localization of the peptide receptor on the 
endothelial cells provokes the translocation of the blood vessel-bound peptide into the injured tissue, 
where the therapeutic payload can exert its functions more potently as it is anchored on the target 
cells in the parenchyma. We were able to show that the anchorage to target cells (outside of 
endothelial cells) provided by CAR peptide fused decorin, enhanced decorin’s biological potency 
against transforming growth factor-β (TGF-β). Later, Hubbell et al. engineered “super” growth factors 
that are more potent than the native ones, simply by fusing the growth factors with the heparin-
binding domain of BMP2 (analogous to the CAR peptide being homologous to BMP4 heparin-binding 
domain) 
7
. 
One of the advantages of using short peptides as targeting elements, is that their small size is unlikely 
to cause an immune reaction. They are only a fraction of the size of the highly variable 
complementary determining regions (CDRs) of therapeutic antibodies, which usually have an excellent 
drug safety and a low immunogenic potential 
11
. Furthermore, homology analysis (by BLAST) of these 
short and stable cyclic peptides typically reveals a high homology to parts of native proteins that are 
highly conserved across a range of species (as for example for CRK and CAR) 
28
. This would predict 
high tolerance of the peptide by the immune system. 
These pharmacological properties highlight the importance of advancing multi-functional, 
systemically administered, target-seeking recombinant fusion proteins. However, unless the target of 
a homing peptide is known to be unimportant for function of the immune system, cell proliferation, 
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angiogenesis, etc., one cannot rule out the possibility of adverse effects caused by high doses of a 
homing peptide binding to its target receptor. Thus, it is necessary to elucidate the target and 
mechanism of homing peptides, and to investigate their safety. 
7. Unconjugated delivery - Bystander effect
The latest innovation to enhance therapeutic drug targeting is a tissue-penetrating transport system 
for certain targeting peptides, which does not require any physical conjugation between the 
therapeutic and targeting elements 
45-47
. The essential features of this system called the “Bystander 
effect” (Figure 3) were first elucidated using a new RGD (RGD is an integrin binding sequence) 
peptide, termed iRGD because it internalizes into target cells 
45-47
. Like conventional RGD peptides, 
iRGD accumulates at tumor vasculature where it binds to integrin, but it is then cleaved by a protease 
to unmask a second binding motif, a so-called CendR motif (consensus: R/KXXR/K in the C-terminal 
end of the peptide after the cleavage) 
45-47
. The CendR motif binds to neuropilin-1, which activates a 
transport tissue-penetration and cell internalization pathway 
45-47
. As the CendR pathway is a bulk 
transport system, it will, once activated, sweep along (through cells) any molecule from large proteins 
to nanoparticles (“Bystander effect”) present in the environment 
45-47
 (Figure 3). Thus, the therapeutic 
molecule can be simply co-injected with the vascular iRGD homing peptide able to induce the 
bystander effect which will sweep the drug molecule into the target organ. Interestingly, even large 
recombinant proteins, such as antibodies, can be transported in target organ-specific fashion using 
vascular homing peptides capable of inducing the “Bystander effect” 
45-47
 (Figure 3). 
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We have recently found that the vascular homing peptide CAR, which does not contain a CendR-
sequence, is a very potent inducer of a bystander effect in pulmonary arterial hypertension (PAH) 
48
 
(Figure 4). Namely, the CAR peptide targets inflammatory vasculature in experimental models of PAH 
and penetrates to inflammatory lung parenchyma 
48, 49
. Remarkably, any vasodilator drug can become 
a target organ-specific vasodilator in that model of PAH 
48
 (Figure 4). When a low dose of a vasodilator 
is co-injected with CAR peptide, the drug accumulates in the diseased lungs and lowers the 
hypertension selectively only in the pulmonary circulation, but does not affect the systemic 
circulation, i.e. no vasodilation occurs 
48
. This effect presents a new paradigm in the treatment of 
PAH, where the clinical application of new, potential therapeutic agents has generally been hampered 
by their systemic toxicity/adverse effects 
48
 (Figure 4). Whether CAR- and CendR-peptides induce a 
bystander effect that may be applicable for therapeutic benefits in regenerative medicine, remains to 
be examined. But the capability of transporting such large proteins as antibodies, could open avenues 
for targeting therapeutic proteins to their intended target organ or tissue via the “Bystander effect” 
(Figure 4). 
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Figure 4. CAR peptide homes to inflammatory vasculature and induced target-tissue selective 
vasodilation in pulmonary arterial hypertension (PAH). (a) PAH was induced in rats by a single 
subcutaneous injection of SU5416 and 3 week exposure to hypoxia (10% O2) followed by 6 
weeks of normoxia 
48
. CAR peptide accumulates in remodeled pulmonary arteries (A/C: 
occlusive neointimal formation) 
49
. A small signal was detected in lung lesions of the PAH rats 
administered with CAR mutant peptide. (b) Effect of CAR (0.3 mg/kg) and of Rho-kinase inhibitor 
Y27632 (1 mg/kg) mixture on right ventricle (RVSP) and left ventricle LVSP systolic pressure. The 
CAR/Y27632 combination treatment induced a marked pulmonary-specific vasodilation RVSP 
with only a minimum effect on LVSP. When Y27632 or CAR was given alone at the same dose (1 
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mg/kg or 0.3 mg/kg, respectively), a small effect was observed in RVSP and LVSP (data not 
shown). (c) Schematic illustration of targeted delivery by the “Bystander effect” induced by 
vascular homing peptide CAR. 
8. CAR-decorin – a target organ-specific, systemically administered, anti-fibrotic molecule
Decorin (DCN) is the best characterized member of the small leucine rich proteoglycan (SLRP) family 
of extracellular matrix (ECM) proteins 
50
. Due to its close interactions with collagen fibers in the ECM, 
i.e. DCN “decorates” collagen fibers, the proteoglycan was named decorin early on 
51
. It has 
substantial interest to clinical medicine owing to its well established anti-fibrotic, anti-cancer and pro-
regenerative effects 
50
.
DCN was initially cloned in 1986 and thought at the time to be a structural constituent of the ECM 
51
. 
However, soon it was established that DCN had a role beyond just a structural component of the ECM, 
as it became evident that it influenced cellular functions such as proliferation, spreading, migration 
and differentiation, as well as being a physiological regulator of inflammation 
52-54
. Some of these 
early findings were derived from tumor cells, where it was shown that DCN inhibited cancer cell 
proliferation and spreading 
52, 55
. These early studies as well as intensive research during past two 
decades have firmly established DCN as a tumor suppressor gene as well as a promising anti-tumor 
agent to treat human cancer patients 
50
. 
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Mammalian DCN contains a monomeric protein core of 42 kDa and a single chondroitin/dermatan 
sulfate glycosaminoglycan (GAG) chain, attached to a serine residue near the N terminus (Figure 5) 
50
. 
DCN exists as a dimer in physiological solutions and as a monomer when bound to collagen (Figure 5) 
56
, and is the best characterized member of the growing family of SLRPs. Structurally, it has a domain 
of tandem leucine-rich repeats (LRRs, altogether 12 LRRs), flanked on both sides by two cysteine-rich 
regions (Figs. 5 & 6) 
50
. 
Figure 5. Structure of decorin. Mammalian decorin (DCN) contains a monomeric protein core of 
42 kDa and a single chondroitin/dermatan sulfate glycosaminoglycan (GAG) chain. DCN exists as 
a dimer in physiological solutions and is the best characterized member of the growing family of 
SLRPs. Structurally, it has a domain of tandem leucine-rich repeats (LRRs, altogether 12 LRRs), 
flanked on both sides by two cysteine-rich regions. Decorin dimer structure (from PDB 1XKU). 
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Images prepared with JMOL program. The N-terminus is in the "middle" of the anti-parallel 
homodimer. 
Anti-fibrotic function of DCN is related to it being a natural inhibitor of TGF-β that shuts down the 
TGF-β responses related to injury, cancer growth and inflammation 
52, 54, 57, 58
. The scar-inducing 
activities of TGF-β1 in fibroblasts are mediated by connective tissue growth factor (CTGF/CCN2) and 
epidermal growth factor (EGF) family receptors (ERBBs) 
59
. CCN2 activity requires the presence of EGF. 
Interestingly, DCN also neutralizes CCN2 
60
 and also EGF by binding to ERBBs 
61-63
 (Figure 6). The active 
sites for TGF-β, CCN2, and EGF neutralization reside in different parts of the DCN molecule 
64
. Thus, in 
theory, a single DCN molecule could simultaneously block multiple mediators of scarring 
64
 (Figure 6). 
Moreover, DCN also inhibits myostatin 
65, 66
, an important contributor to scarring in some organs 
(Figure 6). Owing to this multifunctionality, DCN may be superior to therapeutic approaches that only 
inhibit TGF-β 
64
. The ability of recombinant DCN to prevent scar formation and fibrosis and to 
simultaneously promote tissue regeneration has been demonstrated in numerous experimental tissue 
injury- and disease-models 
50, 54, 57
. 
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Figure 6. Decorin interacts with multiple growth factor signaling pathways crucial for cancer 
growth. Schematic drawing of the molecular structure of decorin (DCN). All four domains I–IV of 
decorin core protein are indicated. DCN has a monomeric protein core and a single 
chondroitin/dermatan sulfate glycosaminoglycan (GAG) chain. Structurally, it has a domain of 
tandem leucine-rich repeats (LRR), flanked on both sides by two cysteine-rich regions. DCN 
interacts with a wide set of different signaling molecules, among them different isoforms of 
transforming growth factor-β (TGFβ), platelet-derived growth factor (PDGF), epidermal growth 
factor receptor (EGFR) and ErbB1 - 4 receptor tyrosine kinases, myostatin (MyoS), connective 
tissue growth factor/CCN2 (CTGF), thrombospondin (Thbs), collagen (Col) and fibronectin (FN), 
implicated in cancer progression. The active/binding sites of DCN for TGF-β, CCN2, c-Met and 
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EGFR neutralization/binding all reside in different parts of the DCN molecule. Thus, in theory, a 
single DCN molecule could simultaneously sequester multiple important mediators of tumor 
growth and antagonize multiple signaling pathways crucial for tumor growth and progression. 
Thus, owing to this multi-functionality, DCN may exert its anti-cancer effects through multiple 
molecular approaches that all contribute to varying degree to its biological effects on cancer 
cells and tumor environment. 
We have recently developed a systemically administered, targeted, e.g. inflammation- and 
angiogenesis-homing version of DCN core protein (Figure 7) 
42
. The angiogenesis- and inflammation-
specificity of this enhanced DCN core protein is achieved by a fusion to the CAR homing peptide that 
works as an address tag in the fusion protein and delivers systemically administered CAR-DCN to 
angiogenic and inflammatory vasculature (Figure 7) 
42
. CAR-DCN peptide can deliver increased 
amounts of DCN in a tissue-specific manner with a significant therapeutic advantage over ordinary 
DCN core protein in healing skin wounds (Figure 7) 
42
. Furthermore, the fusion of CAR to recombinant 
DCN enhances its neutralization activity of TGF-β and provides the desired selectivity against the 
fibrotic isoforms of TGF-β 
42
. The molecular explanation for the enhanced biological activity of CAR-
DCN is that the CAR peptide binds to HSPGs on the target cells. TGF-β1, and TGF-β2 in turn, also bind 
heparan sulfate and HSPG binding increases their biological activity (Figure 7) 
42, 64
. Thus, CAR 
mediated binding of CAR–DCN to HSPGs may enhance the neutralizing effect of the fusion protein by 
bringing it into the proximity of the HSPG-binding TGF-βs 
42, 64
 (Figure 7). More recently, we have 
shown that CAR-DCN reduces the severity of abdominal aortic aneurysm. 
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Figure 7. Schematic illustration of the mechanism of action of the systemically administered, 
target-organ specific anti-fibrotic molecule CAR-decorin. CAR-decorin (1) is a systemically 
administered, target-seeking, multi-functional biotherapeutic that inhibits scar formation. It can 
be targeted to an injury taking place at any organ of the body (2, 3) (or multiple organs 
simultaneously). The CAR homing peptide as part of the fusion protein targets angiogenic 
vasculature, which forms at the site of the injury (4, 5). The CAR peptide and any payload 
attached to it (Blue stars) then extravasates into surrounding tissue (6), where it binds to its 
receptor(s) on the cell surface of the scar producing fibroblasts (7). CAR binding to heparan 
sulfate proteoglycans (HSPGs) provides docking sites in the proximity of the main scar-inducing 
growth factors TGF-β1 and TGF-β2 (8) facilitating the neutralization of these growth factors by 
the therapeutic part of the molecule, decorin (8). This mechanism results in therapeutic 
response (9) seen as reduced scar formation in the skin. Picture by Helena Schmidt; reproduced 
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with permission from Finnish Medical Journal Duodecim (originally published in Duodecim 
2011;127:50-51). 
Targeting lung vasculature in PAH using nanoscale drug delivery systems 
Therapeutic delivery of drugs through the lungs for local bronchodilatory and anti-inflammatory 
effects is the most effective way of managing chronic inflammatory diseases– asthma and chronic 
obstructive pulmonary disorders (COPD) 
67
. Lung delivery of therapeutic proteins, such as insulin, has 
also gained momentum in this decade 
68
. A handful of studies have shown that pulmonary specific 
delivery of anti-PAH drugs could be a better alternative to the oral or intravenous therapies 
69-72
. 
Different small or large molecules with therapeutic potential can be packaged into lipid or polymer-
based nanocarriers which can be modified to offer advantages like prolongation of drug release, deep 
lung deposition for efficient drug absorption 
69-75
. Moreover, by modifying the surface of the particles 
with CAR-peptide, those particles can be targeted to the diseased vasculature for selective effects 
70,
72, 74
. In the present review, we have discussed the methods, advantages and future aspects of homing 
different inhalable nanocarriers towards the remodeled arteries by using CAR peptide for the 
treatment of pulmonary arterial hypertension (Figure 8). 
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Figure 8. Peptide-targeted pulmonary arterial homing approaches of different nanocarriers. 
PEG-polyethylene glycol. 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peptide-micelle conjugates 
Micelles, the donut-shaped nanostructures that are composed of amphiphilic block copolymers, are 
considered more stable than the liposomes, has higher drug entrapment capability and are small in 
size as low as ∼10 nm. Polyethylene glycol–distearoyl-phosphoethanolamine (DSPE–PEG5000), a 
copolymer that was used to encapsulate a number of drugs in micellar forms, has been used to 
prepare CAR-conjugated micelles of fasudil, an investigational vasodilator for PAH 
70
. The resultant 
peptide-micelles hybrid had aerodynamic properties suitable for deep-lung deposition and moderate 
drug entrapment efficiency. These CAR-modified micelles of fasudil was effectively taken up by the 
HSPGs expressing pulmonary arterial smooth muscle cells suggesting PAH vascular specific targeting. 
In-vivo absorption studies of these micelles suggests that the formulation extended the plasma half-
life of the drug by ∼15 times. CAR-micelles of fasudil were also found more selective in reducing 
mean pulmonary arterial pressure in monocrotaline-induced PAH rats than that of unmodified fasudil 
micelles, suggesting a strong diseased pulmonary artery specific targeting in PAH 
70
. 
Peptide conjugated nanoerythrosomes 
Nanoerythrosomes (NERs) are the vesicles prepared by the extrusion of white unsealed red blood cell 
(RBC) ghosts. RBC ghosts are prepared by several round of hemolysis with hypotonic solutions. 
Derived from a biomimetic natural origin, NERs offer several advantages like lower propensity of 
forming aggregates, higher drug retention capacity and long circulation time. Conjugation of targeting 
moieties onto the surface of the NER is comparatively straight forward due to the abundance of 
amine groups on the surface of the NERs 
76, 77
. CAR-peptide conjugated NERs loaded with fasudil was 
respirable and was preferentially uptaken by the TGF-β induced HSPGs expressing pulmonary arterial 
smooth muscle cells (PASMC) 
77
. CAR-conjugated fasudil NERs, when administered intratracheally to 
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the MCT induced PAH rats, showed pulmonary selective vasodilation with minimum perturbation on 
the systemic pressures as compared to that of the unmodified NER containing fasudil 
77
. Upon 
pulmonary administration CAR conjugated fasudil NERs was twice more selective than the unmodified 
fasudil NERs as calculated by the lung targeting indices 
77
. Overall, CAR-conjugated NERs can be used 
as a suitable targeted biomimetic system for delivering anti-PAH therapeutics to the diseased 
vasculature more efficiently. 
Peptide conjugated liposomes 
In last five decades, liposomes– the closed bilayered nanospheres composed of phospholipids– gained 
tremendous interest as a drug delivery system for encapsulating a diverse range of therapeutic small 
and large molecules that are distinct in terms of physicochemical properties 
78, 79
. These self-
assembled nanocarriers can encapsulate both hydrophilic and hydrophobic drugs, offers several 
benefits such as good solubilization, colloidal, chemical and biological stability and scope of surface 
modification for targeting 
79, 80
. After pulmonary administration, CAR-peptide linked liposomal 
formulation of fasudil prolonged the drug half-life by 34-folds, can evade alveolar macrophage 
clearance, and was preferentially taken up by the TGF-β activated PASMCs. Efficacy studies in PAH 
rats reveals that CAR-conjugated inhalable liposomes showed pulmonary-specific vasodilation as 
compared to that of the unmodified fasudil liposomes 
71
. A separate study reports that two drugs, 
fasudil and a reactive oxygen species scavenger– super oxide dismutase (SOD), can also be 
encapsulated in the same liposome while retaining the CAR peptide attached on the surface 
72
. This 
dual-drug approach with site-targeted liposomes has important clinical relevance as the development 
of PAH involves multiple pathobiological pathways and are usually managed different combination 
therapies. 
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Future challenges 
Although targeted nanocarriers showed good promise in producing selective anti-PAH effects in the 
diseased vasculature of the animals after single administration, thorough long-term safety and 
efficacy studies must be established before any clinical translation can be made. Steady-state 
pharmacokinetics of the drugs after repeated administration is needed to be correlated with 
pharmacodynamic effects. In case of combination therapies, potential pharmacokinetic and 
pharmacodynamic interactions are required to be investigated. PLGA-based solid microparticles are 
often preferred in designing inhalable therapeutics because of their trusted safety profile, superior 
biodegradability and biocompatibility, better stability for being in solid powder form and the flexibility 
of surface (stealthing) and core-modification (porosity) 
69, 73, 81, 82
 However, surface modification of 
PLGA-based nanospheres with peptides is challenging mostly because of protein/peptide 
denaturation in the harsh organic solvents that are used in particle preparation. Developing a protein-
friendly particle preparation technique with step-wise optimization and the selection of a suitable 
polymer might be helpful in developing a peptide-coated solid inhalable particles of anti-PAH drugs 
83
. 
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Figure 1. Target-specific drug therapies in tissue regeneration. Molecular “Zip/postal codes” in the 
angiogenic vasculature of the regenerating tissues allow target organ-specific delivery of the systemically 
administered therapeutic recombinant proteins by affinity-based physical targeting (using peptides or 
antibodies as an “address tag”) to injured tissues undergoing repair. The desired outcome of the targeted 
therapies is similar to topical application: increased local accumulation of the recombinant protein in the 
target tissue and lower systemic concentration of the therapeutic payload.  
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Figure 2. Schematic presentation of the principle of in vivo phage display. (a) A cyclic CX7C-peptide library 
has been cloned to the C-terminus of the phage coat protein and expressed in 415 copies in T7 Select 415-
1b phage. (b) A phage library is injected into circulation. The homing peptides on the phage surface bind to 
endothelium in the tissues, resulting in an enrichment of phages bound to the endothelium of the target 
tissue. Target tissue is homogenized, cell suspensions prepared, and the bound phage rescued and amplified 
by adding E. coli. The amplified phage pool recovered from the target tissue is then re-injected into mice at 
a similar disease stage, and the screening cycle is repeated several times to ensure that phage clones that 
specifically bind (i.e. home) towards target will be recovered. A set of phage clones is randomly collected 
from a homing phage population that shows enriched homing towards target tissue. The peptide-encoding 
DNA inserts are amplified by PCR, and the PCR products sequenced.  
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Figure 3. Systemically administered, targeted therapies. (a) Conjugated delivery. The drugs are physically 
conjugated to the targeting element in conventional drug targeting. For protein-based therapeutics, 
targeting domain and therapeutic molecule are fused together as a recombinant protein with enhanced 
activity and tissue-specificity. (b) – (c) Bystander effect. Therapeutic drug(s) co-injected with tissue-
penetrating targeting peptides are transported across the vessel wall and through tissue together with the 
peptides. No actual physical connection is needed between them; the cell penetrating homing peptide 
“sweeps” co-injected drug(s) to its target (homing) tissue in a tissue-specific fashion.  
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Figure 4. CAR peptide homes to inflammatory vasculature and induced target-tissue selective vasodilation in 
pulmonary arterial hypertension (PAH). (a) PAH was induced in rats by a single subcutaneous injection of 
SU5416 and 3 week exposure to hypoxia (10% O2) followed by 6 weeks of normoxia 48. CAR peptide 
accumulates in remodeled pulmonary arteries (A/C: occlusive neointimal formation) 49. A small signal was 
detected in lung lesions of the PAH rats administered with CAR mutant peptide. (b) Effect of CAR (0.3 
mg/kg) and of Rho-kinase inhibitor Y27632 (1 mg/kg) mixture on right ventricle (RVSP) and left ventricle 
LVSP systolic pressure. The CAR/Y27632 combination treatment induced a marked pulmonary-specific 
vasodilation RVSP with only a minimum effect on LVSP. When Y27632 or CAR was given alone at the same 
dose (1 mg/kg or 0.3 mg/kg, respectively), a small effect was observed in RVSP and LVSP (data not shown). 
(c) Schematic illustration of targeted delivery by the “Bystander effect” induced by vascular homing peptide 
CAR.  
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Figure 5. Structure of decorin. Mammalian decorin (DCN) contains a monomeric protein core of 42 kDa and 
a single chondroitin/dermatan sulfate glycosaminoglycan (GAG) chain. DCN exists as a dimer in 
physiological solutions and is the best characterized member of the growing family of SLRPs. Structurally, it 
has a domain of tandem leucine-rich repeats (LRRs, altogether 12 LRRs), flanked on both sides by two 
cysteine-rich regions. Decorin dimer structure (from PDB 1XKU). Images prepared with JMOL program. The 
N-terminus is in the "middle" of the anti-parallel homodimer.  
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